Timothy Cloughesy - Publications

Affiliations: 
University of California, Los Angeles, Los Angeles, CA 

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Hagiwara A, Yao J, Raymond C, Cho NS, Everson R, Patel K, Morrow DH, Desousa BR, Mareninov S, Chun S, Nathanson DA, Yong WH, Andrei G, Divakaruni AS, Salamon N, ... ... Cloughesy TF, et al. "Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. Neuroimage. Clinical. 32: 102882. PMID 34911188 DOI: 10.1016/j.nicl.2021.102882  1
2021 Hagiwara A, Oughourlian TC, Cho NS, Schlossman J, Wang C, Yao J, Raymond C, Everson R, Patel K, Mareninov S, Rodriguez FJ, Salamon N, Pope WB, Nghiemphu PL, Liau LM, ... ... Cloughesy TF, et al. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro-Oncology. PMID 34865129 DOI: 10.1093/neuonc/noab276  1
2021 Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, Kienzler JC, Everson RG, Nathanson DA, Bensinger SJ, Liau LM, Cloughesy T, Hugo W, Prins RM. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications. 12: 6938. PMID 34836966 DOI: 10.1038/s41467-021-26940-2  1
2021 Ellingson BM, Kim GHJ, Brown M, Lee J, Salamon N, Steelman L, Hassan I, Pandya SS, Chun S, Linetsky M, Yoo B, Wen PY, Mellinghoff IK, Goldin J, Cloughesy TF. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib. Neuro-Oncology. PMID 34751786 DOI: 10.1093/neuonc/noab256  1
2021 Bi J, Khan A, Tang J, Armando AM, Wu S, Zhang W, Gimple RC, Reed A, Jing H, Koga T, Wong IT, Gu Y, Miki S, Yang H, Prager B, ... ... Cloughesy TF, et al. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports. 37: 109957. PMID 34731610 DOI: 10.1016/j.celrep.2021.109957  1
2021 Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley MC, Merchant F, Abrey LE, Allen JE, Aguilar LK, Aguilar-Cordova E, Arons D, Tanner K, Bagley S, Khasraw M, ... Cloughesy T, et al. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. The Lancet. Oncology. 22: e456-e465. PMID 34592195 DOI: 10.1016/S1470-2045(21)00488-5  1
2021 Ellingson BM, Wen PY, Cloughesy TF. Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. Cancer Journal (Sudbury, Mass.). 27: 395-403. PMID 34570454 DOI: 10.1097/PPO.0000000000000543  1
2021 Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E, Chang SM, Nabors LB, Ahluwalia MS, Stupp R, Mehta MP, Reardon DA, Grossman SA, Sulman EP, Sampson JH, ... ... Cloughesy TF, et al. Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34561269 DOI: 10.1158/1078-0432.CCR-21-2750  1
2021 Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, ... ... Cloughesy TF, et al. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neuro-Oncology Advances. 3: vdab082. PMID 34377989 DOI: 10.1093/noajnl/vdab082  1
2021 Wang C, Van Dyk K, Cho N, Raymond C, Choi J, Salamon N, Pope WB, Lai A, Cloughesy TF, Nghiemphu PL, Ellingson BM. Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). Brain Imaging and Behavior. PMID 34350525 DOI: 10.1007/s11682-021-00497-6  1
2021 Lu Y, Ng AHC, Chow FE, Everson RG, Helmink BA, Tetzlaff MT, Thakur R, Wargo JA, Cloughesy TF, Prins RM, Heath JR. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nature Communications. 12: 4031. PMID 34188042 DOI: 10.1038/s41467-021-24293-4  1
2021 Sharaf R, Pavlick DC, Frampton GM, Cooper M, Jenkins J, Danziger N, Haberberger J, Alexander BM, Cloughesy T, Yong WH, Liau LM, Nghiemphu PL, Ji M, Lai A, Ramkissoon SH, et al. Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncology Advances. 3: vdab059. PMID 34169283 DOI: 10.1093/noajnl/vdab059  1
2021 Tatekawa H, Uetani H, Hagiwara A, Bahri S, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. Annals of Nuclear Medicine. PMID 34121166 DOI: 10.1007/s12149-021-01637-0  1
2021 He L, Bhat K, Ioannidis A, Zhang L, Nguyen NT, Allen JE, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34097975 DOI: 10.1016/j.radonc.2021.05.027  1
2021 Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, ... ... Cloughesy TF, et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human Phase I trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34078652 DOI: 10.1158/1078-0432.CCR-21-0611  1
2021 Sharaf R, Pavlick DC, Frampton GM, Cooper M, Jenkins J, Danziger N, Haberberger J, Alexander BM, Cloughesy T, Yong WH, Liau LM, Nghiemphu PL, Ji M, Lai A, Ramkissoon SH, et al. FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncology Advances. 3: vdab017. PMID 33778493 DOI: 10.1093/noajnl/vdab017  1
2021 Tatekawa H, Uetani H, Hagiwara A, Yao J, Oughourlian TC, Ueda I, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Bahri S, Pope WB, Salamon N, Ellingson BM. Preferential tumor localization in relation to F-FDOPA uptake for lower-grade gliomas. Journal of Neuro-Oncology. PMID 33704629 DOI: 10.1007/s11060-021-03730-w  1
2021 Tatekawa H, Hagiwara A, Uetani H, Bahri S, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 21: 27. PMID 33691798 DOI: 10.1186/s40644-021-00396-5  1
2021 Zhou H, Lin S, Li X, Guo D, Wang Y, Hu Y. Serum miR-222 is independently associated with atrial fibrillation in patients with degenerative valvular heart disease. Bmc Cardiovascular Disorders. 21: 98. PMID 33593281 DOI: 10.1186/s12872-021-01909-7  0.01
2021 Lassman AB, Cloughesy TF. Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile? Neuro-Oncology. PMID 33560350 DOI: 10.1093/neuonc/noab006  1
2021 Bhat K, Saki M, Cheng F, He L, Zhang L, Ioannidis A, Nathanson D, Tsang J, Bensinger SJ, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. Journal of the National Cancer Institute. PMID 33556960 DOI: 10.1093/jnci/djab018  1
2020 Chuntova P, Chow F, Watchmaker P, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, ... ... Cloughesy T, et al. Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Neuro-Oncology. PMID 33367885 DOI: 10.1093/neuonc/noaa277  1
2020 Chen H, Kuhn J, Lamborn KR, Abrey LE, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WKA, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, ... ... Cloughesy TF, et al. Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neuro-Oncology Advances. 2: vdaa124. PMID 33235994 DOI: 10.1093/noajnl/vdaa124  1
2020 Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H, van den Bent MJ, Wen PY, Yung WKA, Cloughesy TF, Goldin JG. Radiographic Read Paradigms and the Roles of the Central Imaging Laboratory in Neuro-Oncology Clinical Trials. Neuro-Oncology. PMID 33130879 DOI: 10.1093/neuonc/noaa253  1
2020 Sakai Y, Yang C, Kihira S, Tsankova N, Khan F, Hormigo A, Lai A, Cloughesy T, Nael K. MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting. International Journal of Molecular Sciences. 21. PMID 33121211 DOI: 10.3390/ijms21218004  1
2020 Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, et al. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. Jama Oncology. PMID 33119048 DOI: 10.1001/jamaoncol.2020.3161  1
2020 Oughourlian TC, Yao J, Hagiwara A, Nathanson DA, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. Neuroradiology. PMID 33106922 DOI: 10.1007/s00234-020-02585-8  1
2020 Wu X, Geng F, Cheng X, Guo Q, Zhong Y, Cloughesy TF, Yong WH, Chakravarti A, Guo D. Lipid Droplets Maintain Energy Homeostasis and Glioblastoma Growth via Autophagic Release of Stored Fatty Acids. Iscience. 23: 101569. PMID 33083736 DOI: 10.1016/J.Isci.2020.101569  1
2020 Patel KS, Kejriwal S, Thammachantha S, Duong C, Murillo A, Gordon LK, Cloughesy TF, Liau L, Yong W, Yang I, Wadehra M. Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab. Neuro-Oncology Advances. 2: vdaa112. PMID 33063013 DOI: 10.1093/noajnl/vdaa112  1
2020 Tsang JE, Urner LM, Kim G, Chow K, Baufeld L, Faull K, Cloughesy TF, Clark PM, Jung ME, Nathanson DA. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. Acs Medicinal Chemistry Letters. 11: 1799-1809. PMID 33062157 DOI: 10.1021/Acsmedchemlett.9B00599  1
2020 Tatekawa H, Yao J, Oughourlian TC, Hagiwara A, Wang C, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Salamon N, Ellingson BM. Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study. Clinical Nuclear Medicine. PMID 33031233 DOI: 10.1097/RLU.0000000000003318  1
2020 Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, et al. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. PMID 32965680 DOI: 10.1002/cncr.33171  0.01
2020 Tatekawa H, Hagiwara A, Uetani H, Yao J, Oughourlian TC, Bahri S, Wang C, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. Journal of Neuro-Oncology. PMID 32929644 DOI: 10.1007/s11060-020-03613-6  1
2020 Patel KS, Yao J, Raymond C, Yong W, Everson R, Liau LM, Nathanson D, Kornblum H, Wang C, Oughourlian T, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. Scientific Reports. 10: 14819. PMID 32908231 DOI: 10.1038/S41598-020-71799-W  1
2020 Johnson RM, Phillips HS, Bais C, Brennan CW, Cloughesy TF, Daemen A, Herrlinger U, Jenkins RB, Lai A, Mancao C, Weller M, Wick W, Bourgon R, Garcia J. Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. Neuro-Oncology. PMID 32897363 DOI: 10.1093/Neuonc/Noaa157  1
2020 Stefanaki I, Stratigos AJ, Kypreou KP, Evangelou E, Gandini S, Maisonneuve P, Polsky D, Lazovich D, Newton-Bishop J, Kanetsky PA, Puig S, Gruis NA, Ghiorzo P, Pellegrini C, De Nicolo A, et al. MC1R variants in relation to naevi in melanoma cases and controls: a pooled-analysis from the M-SKIP project. Journal of the European Academy of Dermatology and Venereology : Jeadv. PMID 32780924 DOI: 10.1111/Jdv.16869  0.01
2020 Yao J, Hagiwara A, Raymond C, Shabani S, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Scientific Reports. 10: 11922. PMID 32681084 DOI: 10.1038/s41598-020-68733-5  1
2020 Tatekawa H, Hagiwara A, Yao J, Oughourlian TC, Ueda I, Uetani H, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. Voxel-Wise and Patient-Wise Correlation of F-FDOPA PET, rCBV, and ADC in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32646876 DOI: 10.2967/jnumed.120.247411  1
2020 Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy. Neuro-Oncology. PMID 32615600 DOI: 10.1093/neuonc/noaa154  1
2020 Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, ... ... Cloughesy TF, et al. Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903327. PMID 32530764 DOI: 10.1200/Jco.19.03327  1
2020 Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. European Journal of Neurology. PMID 32526057 DOI: 10.1111/ene.14393  0.01
2020 Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, Kaufmann TJ, Barboriak DP, Huang RH, Wick W, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, ... ... Cloughesy TF, et al. Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas. Neuro-Oncology. PMID 32516388 DOI: 10.1093/Neuonc/Noaa141  1
2020 Reardon DA, Desjardins A, Rixe O, Cloughesy T, Alekar S, Williams JH, Li R, Taylor CT, Lassman AB. A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Investigational New Drugs. PMID 32436060 DOI: 10.1007/s10637-020-00950-1  1
2020 Patel KS, Everson RG, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, et al. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. Neurosurgery. PMID 32365185 DOI: 10.1093/neuros/nyaa135  1
2020 Bhat K, Saki M, Vlashi E, Cheng F, Duhachek-Muggy S, Alli C, Yu G, Medina P, He L, Damoiseaux R, Pellegrini M, Zemke NR, Nghiemphu PL, Cloughesy TF, Liau LM, et al. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 32358191 DOI: 10.1073/Pnas.1920154117  1
2020 Wen PY, Weller M, Lee EQ, Alexander BA, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, et al. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro-Oncology. PMID 32328653 DOI: 10.1093/Neuonc/Noaa106  1
2020 Huang RY, Young RJ, Ellingson BM, Veeraraghavan H, Wang W, Tixier F, Um H, Nawaz R, Luks T, Kim J, Gerstner ER, Schiff D, Peters KB, Mellinghoff IK, Chang S, ... Cloughesy TF, et al. Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment. Neuro-Oncology. PMID 32328652 DOI: 10.1093/Neuonc/Noaa105  1
2020 Frederic F, Soraya B, Anne-Sophie A, Aurelie A, David A. Gender-related differences in the facial aging of Caucasian French subjects and their relations with perceived ages and tiredness. Journal of Cosmetic Dermatology. PMID 32315489 DOI: 10.1111/jocd.13446  0.01
2020 Ellingson BM, Yao J, Raymond C, Nathanson DA, Chakhoyan A, Simpson J, Garner JS, Olivero AG, Mueller LU, Rodon J, Gerstner E, Cloughesy TF, Wen PY. Multi-parametric MR-PET imaging predicts pharmacokinetics and clinical response to GDC-0084 in patients with recurrent high-grade glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32269051 DOI: 10.1158/1078-0432.CCR-19-3817  1
2020 Cho N, Wang C, Raymond C, Kaprealian T, Ji M, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. Journal of Neuro-Oncology. PMID 32239430 DOI: 10.1007/s11060-020-03460-5  1
2020 Ji MS, Eldred BSC, Liu R, Pianka ST, Molaie D, Kevan B, Pan S, Lai TJ, Nguyen NT, Chow FE, Yong WH, Cox CD, Reeh DN, Li T, Liau LM, ... ... Cloughesy TF, et al. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience. Neuro-Oncology Advances. 2: vdaa009. PMID 32118206 DOI: 10.1093/noajnl/vdaa009  1
2020 Oughourlian TC, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Rate of change in maximum F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. Journal of Neuro-Oncology. PMID 31981013 DOI: 10.1007/S11060-020-03407-W  1
2020 Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, Lee EQ, Rodon J. First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31937616 DOI: 10.1158/1078-0432.CCR-19-2808  1
2020 Antonios JP, Everson RG, Mochizuki A, Khattab S, Soto H, Romiyo P, Sun MZ, Moughon D, Billingslea-Yoon E, Odesa S, Li G, Kawaguchi E, Salazar A, Yong W, Schlossman J, ... ... Cloughesy T, et al. Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-Pr13  1
2020 Wen PY, Groot Jd, Battiste JD, Goldlust SA, Garner JS, Simpson JA, Kijlstra J, Olivero A, Cloughesy T. Abstract CT205: Phase 2 study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct205  1
2019 Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, et al. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Management and Research. 11: 10463-10476. PMID 31853198 DOI: 10.2147/CMAR.S208720  1
2019 Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Shmueli SF, Wen PY. A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro-Oncology. PMID 31844890 DOI: 10.1093/neuonc/noz232  1
2019 Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, Peretz I, Oberman B, Freedman LS, Ellingson BM, Cloughesy TF, Sher N, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, et al. Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro-Oncology. PMID 31844886 DOI: 10.1093/neuonc/noz231  1
2019 Masui K, Harachi M, Ikegami S, Yang H, Onizuka H, Yong WH, Cloughesy TF, Muragaki Y, Kawamata T, Arai N, Komori T, Cavenee WK, Mischel PS, Shibata N. mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma. The Journal of Biological Chemistry. PMID 31712311 DOI: 10.1074/Jbc.Ra119.011519  1
2019 Nguyen HT, Nguyen N, Liu LY, Dovek L, Lenchner D, Harris R, Ozer B, Ravelo A, Sommer N, Sim MS, Elashoff R, Green R, Nghiemphu PL, Cloughesy TF, Ellingson B, et al. Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. Neuro-Oncology Practice. 6: 103-111. PMID 31386050 DOI: 10.1093/Nop/Npy021  1
2019 Dovek L, Nguyen NT, Ozer BH, Li N, Elashoff RM, Green RM, Liau L, Nghiemphu PL, Cloughesy TF, Lai A. Correlation of commercially available quantitative (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. Neuro-Oncology Practice. 6: 194-202. PMID 31386024 DOI: 10.1093/Nop/Npy028  1
2019 Villarino NF, Lopez CM, Sams RA, Bayly WM. Pharmacokinetics of furosemide in thoroughbred horses subjected to supramaximal treadmill exercise with and without controlled access to water. Bmc Veterinary Research. 15: 275. PMID 31375096 DOI: 10.1186/s12917-019-2017-3  0.01
2019 Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, ... ... Cloughesy TF, et al. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metabolism. PMID 31303424 DOI: 10.1016/J.Cmet.2019.06.014  1
2019 Liu LY, Ji MS, Nguyen NT, Chow FE, Molaie DM, Pianka ST, Green RM, Liau LM, Ellingson BM, Nghiemphu PL, Cloughesy TF, Lai A. Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. Cns Oncology. CNS35. PMID 31293169 DOI: 10.2217/cns-2019-0007  1
2019 Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology. PMID 31276167 DOI: 10.1093/Neuonc/Noz119  1
2019 McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, et al. Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM. Molecular Cancer Therapeutics. PMID 31270152 DOI: 10.1158/1535-7163.Mct-18-1330  1
2019 Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, et al. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. PMID 31215634 DOI: 10.1093/Neuros/Nyz186  1
2019 Ventz S, Lai A, Cloughesy TF, Wen PY, Trippa L, Alexander BM. Design and evaluation of an external control arm using prior clinical trials and real-world data. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31175098 DOI: 10.1158/1078-0432.CCR-19-0820  1
2019 Vanderbeek AM, Ventz S, Rahman R, Fell G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro-Oncology. PMID 31155679 DOI: 10.1093/neuonc/noz097  1
2019 Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemotherapy and Pharmacology. PMID 31154523 DOI: 10.1007/s00280-019-03879-2  1
2019 Wang YL, Yao J, Chakhoyan A, Raymond C, Salamon N, Liau LM, Nghiemphu PL, Lai A, Pope WB, Nguyen N, Ji M, Cloughesy TF, Ellingson BM. Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. Ajnr. American Journal of Neuroradiology. PMID 31097430 DOI: 10.3174/ajnr.A6063  1
2019 Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro-Oncology. PMID 31066901 DOI: 10.1093/Neuonc/Noz078  1
2019 Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, ... ... Cloughesy T, et al. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Journal of Neuro-Oncology. PMID 30838489 DOI: 10.1007/S11060-019-03126-X  1
2019 Chakhoyan A, Yao J, Leu K, Pope WB, Salamon N, Yong W, Lai A, Nghiemphu PL, Everson RG, Prins RM, Liau LM, Nathanson DA, Cloughesy TF, Ellingson BM. Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Scientific Reports. 9: 2846. PMID 30808879 DOI: 10.1038/S41598-018-37564-W  1
2019 Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. Journal of Neuro-Oncology. PMID 30806888 DOI: 10.1007/s11060-019-03132-z  1
2019 Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine. PMID 30742122 DOI: 10.1038/S41591-018-0337-7  1
2019 Zhang D, Kim SSR, Kelly DF, Asa SL, Movassaghi M, Mareninov S, Yong WH, Cloughesy TF, Rodriguez FJ, McKeever P, Qian J, Li JY, Mao Q, Newell KL, Green RM, et al. Somatostatin Receptor Ligand Therapy-A Novel Therapy for Neurocytoma. The Journal of Clinical Endocrinology and Metabolism. PMID 30722009 DOI: 10.1210/Jc.2018-02419  1
2019 Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, ... ... Cloughesy TF, et al. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801207. PMID 30715997 DOI: 10.1200/Jco.18.01207  1
2018 Davidson TB, Lee AH, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki AY, Antonios JP, Garcia AJ, Kotecha N, Bayless NL, ... ... Cloughesy TF, et al. Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30498094 DOI: 10.1158/1078-0432.Ccr-18-1176  1
2018 Yao J, Ruan D, Raymond C, Liau LM, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Improving B Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. Tomography (Ann Arbor, Mich.). 4: 123-137. PMID 30320212 DOI: 10.18383/j.tom.2018.00017  1
2018 Smedley NF, Ellingson BM, Cloughesy TF, Hsu W. Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. Scientific Reports. 8: 14429. PMID 30258190 DOI: 10.1038/S41598-018-32397-Z  1
2018 Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Cloughesy TF, et al. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 179. PMID 29958537 DOI: 10.1186/S12967-018-1552-1  1
2018 Lee EQ, McFaline-Figueroa JR, Cloughesy TF, Wen PY. Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas? Neuro-Oncology. PMID 29955870 DOI: 10.1093/neuonc/noy092  1
2018 Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, ... ... Cloughesy TF, et al. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide and bevacizumab or placebo. Neuro-Oncology. PMID 29897562 DOI: 10.1093/neuonc/noy064  1
2018 Chakhoyan A, Woodworth DC, Harris RJ, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Ellingson BM. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. Journal of Neuro-Oncology. PMID 29855771 DOI: 10.1007/s11060-018-2910-9  1
2018 Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, ... ... Cloughesy TF, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of Translational Medicine. 16: 142. PMID 29843811 DOI: 10.1186/S12967-018-1507-6  1
2018 Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, et al. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. International Journal of Radiation Oncology, Biology, Physics. 100: 1195-1203. PMID 29722661 DOI: 10.1016/J.Ijrobp.2018.01.001  1
2018 Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. Journal of Neuro-Oncology. PMID 29679199 DOI: 10.1007/S11060-018-2877-6  1
2018 Olar A, Goodman LD, Wani KM, Boehling NS, Sharma DS, Mody RR, Gumin J, Claus EB, Lang FF, Cloughesy TF, Lai A, Aldape KD, DeMonte F, Sulman EP. A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget. 9: 16087-16098. PMID 29662628 DOI: 10.18632/Oncotarget.24498  1
2018 Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, ... ... Cloughesy TF, et al. Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro-Oncology. PMID 29660006 DOI: 10.1093/Neuonc/Noy053  1
2018 Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, ... ... Cloughesy TF, et al. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro-Oncology. PMID 29660005 DOI: 10.1093/neuonc/noy054  1
2018 Harris RJ, Yao J, Chakhoyan A, Raymond C, Leu K, Liau LM, Nghiemphu PL, Lai A, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magnetic Resonance in Medicine. PMID 29626359 DOI: 10.1002/mrm.27204  1
2018 Alexander BM, Cloughesy TF. Platform trials arrive on time for glioblastoma. Neuro-Oncology. PMID 29617844 DOI: 10.1093/neuonc/noy040  1
2018 Li T, Cox CD, Ozer B, Nguyen NT, Nguyen HN, Lai TJ, Li S, Liu F, Kornblum HI, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. D-2-Hydroxyglutarate is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-induced MIR148A Promoter Methylation. Molecular Cancer Research : McR. PMID 29545476 DOI: 10.1158/1541-7786.MCR-17-0367  1
2018 Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro-Oncology. PMID 29518210 DOI: 10.1093/neuonc/noy027  1
2017 Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. PMID 29266174 DOI: 10.1002/Cncr.31172  1
2017 Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. Neuro-Oncology. PMID 29106665 DOI: 10.1093/Neuonc/Nox208  1
2017 Chakhoyan A, Leu K, Pope WB, Cloughesy TF, Ellingson BM. Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. Ajnr. American Journal of Neuroradiology. PMID 29074632 DOI: 10.3174/ajnr.A5433  1
2017 Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski N, Taylor J, Clarke JL, Chang SM, et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29074604 DOI: 10.1158/1078-0432.Ccr-17-0963  1
2017 Ellingson BM, Wen PY, Cloughesy TF. Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma. Neuro-Oncology. PMID 29040703 DOI: 10.1093/neuonc/nox193  1
2017 Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro-Oncology. PMID 29036345 DOI: 10.1093/neuonc/nox151  1
2017 Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, ... ... Cloughesy TF, et al. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nature Medicine. PMID 29035366 DOI: 10.1038/Nm.4418  1
2017 Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro-Oncology. PMID 29016998 DOI: 10.1093/neuonc/nox154  1
2017 Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, et al. Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio. Neuro-Oncology. PMID 29016943 DOI: 10.1093/neuonc/nox162  1
2017 Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, ... ... Cloughesy TF, et al. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. Journal of Neuro-Oncology. PMID 28988377 DOI: 10.1007/S11060-017-2624-4  1
2017 Chung LK, Pelargos PE, Chan AM, Demos JV, Lagman C, Sheppard JP, Nguyen T, Chang YL, Hojat SA, Prins RM, Liau LM, Nghiemphu L, Lai A, Cloughesy TF, Yong WH, et al. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. Brain Tumor Pathology. PMID 28887715 DOI: 10.1007/S10014-017-0300-1  1
2017 Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America. PMID 28874539 DOI: 10.1073/Pnas.1706689114  1
2017 Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28814435 DOI: 10.1158/1078-0432.CCR-17-0764  1
2017 Yu A, Faiq N, Green S, Lai A, Green R, Hu J, Cloughesy TF, Mellinghoff I, Nghiemphu PL. Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. Journal of Neuro-Oncology. PMID 28669012 DOI: 10.1007/s11060-017-2533-6  1
2017 Movassaghi M, Shabihkhani M, Hojat SA, Williams RR, Chung LK, Im K, Lucey GM, Wei B, Mareninov S, Wang MW, Ng DW, Tashjian RS, Magaki S, Perez-Rosendahl M, Yang I, ... ... Cloughesy TF, et al. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Experimental and Molecular Pathology. PMID 28663030 DOI: 10.1016/J.Yexmp.2017.06.006  1
2017 Ellingson BM, Gerstner E, Smits M, Huang RY, Colen RR, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, ... ... Cloughesy TF, et al. Diffusion MRI phenotypes predict overall survival benefitfrom anti-VEGF monotherapy in recurrent glioblastoma:Converging evidence from phase II trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28655794 DOI: 10.1158/1078-0432.Ccr-16-2844  1
2017 Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, et al. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Molecular Cell. PMID 28648777 DOI: 10.1016/J.Molcel.2017.05.030  1
2017 Alexander BM, Cloughesy TF. Adult Glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017730119. PMID 28640706 DOI: 10.1200/JCO.2017.73.0119  1
2017 Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. Journal of Neuro-Oncology. PMID 28547590 DOI: 10.1007/S11060-017-2506-9  1
2017 Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, ... Cloughesy T, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology. 19: 625-635. PMID 28453751 DOI: 10.1093/neuonc/nox029  1
2017 Cloughesy TF, Lassman AB. NovoTTF: where to go from here? Neuro-Oncology. 19: 605-608. PMID 28453750 DOI: 10.1093/neuonc/nox014  1
2017 Clark P, Ebiana VA, Gosa L, Cloughesy TF, Nathanson DA. Harnessing preclinical molecular imaging to inform advances in personalized cancer medicine. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28385796 DOI: 10.2967/jnumed.116.181693  1
2017 Shabihkhani M, Telesca D, Movassaghi M, Naeini YB, Naeini KM, Hojat SA, Gupta D, Lucey GM, Ontiveros M, Wang MW, Hanna LS, Sanchez DE, Mareninov S, Khanlou N, Vinters HV, ... ... Cloughesy TF, et al. Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. Journal of Neuro-Oncology. PMID 28161760 DOI: 10.1007/S11060-017-2377-0  1
2017 Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, et al. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. Journal of Neuro-Oncology. PMID 28116649 DOI: 10.1007/S11060-016-2357-9  1
2017 Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncology. PMID 28115578 DOI: 10.1093/Neuonc/Now287  1
2017 Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 28108885 DOI: 10.1007/s13311-016-0507-6  1
2017 Wei H, Chang H, Zheng L, Lin S, Chen Y, Tian H, Zhao J, Chen Y, Cai H, Gu X, Murugan K. Identification and expression profiling of pheromone biosynthesis activating neuropeptide in Chlumetia transversa (Walker). Pesticide Biochemistry and Physiology. 135: 89-96. PMID 28043337 DOI: 10.1016/j.pestbp.2016.05.005  0.01
2017 Berry DA, Graves T, Connor J, Alexander B, Cloughesy T, Barker A, Berry SM. Abstract 3594: Adaptively randomized seamless-phase multiarm platform trial: Glioblastoma Multiforme Adaptive Global Innovative Learning Environment (GBM AGILE) Cancer Research. 77: 3594-3594. DOI: 10.1158/1538-7445.Am2017-3594  0.01
2016 Ahn C, White P, Liau LM, Cloughesy TF, Nghiemphu PL. Development of an integrated practice unit: Utilizing a lean approach to impact value of care for brain tumor patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 99. PMID 28152815 DOI: 10.1200/jco.2016.34.7_suppl.99  1
2016 Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, et al. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2015647685. PMID 27918718 DOI: 10.1200/Jco.2015.64.7685  1
2016 Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016707562. PMID 27893327 DOI: 10.1200/Jco.2016.70.7562  1
2016 Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J, Desideri S, Grossman S, Ye X, Park DM. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. Journal of Neuro-Oncology. PMID 27826680 DOI: 10.1007/s11060-016-2263-1  1
2016 Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, ... ... Cloughesy TF, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. PMID 27746144 DOI: 10.1016/J.Ccell.2016.09.008  1
2016 Lassman AB, Cloughesy TF. Biomarkers in NOA-04: another piece to the puzzle. Neuro-Oncology. 18: 1467-1469. PMID 27738177 DOI: 10.1093/neuonc/now210  1
2016 Harris RJ, Cloughesy TF, Liau LM, Nghiemphu PL, Lai A, Pope WB, Ellingson BM. Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T. Nmr in Biomedicine. PMID 27717216 DOI: 10.1002/nbm.3611  1
2016 Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, ... Cloughesy TF, et al. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single- and multicenter trials. Neuro-Oncology. PMID 27580889 DOI: 10.1093/neuonc/now187  0.4
2016 Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, et al. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology. PMID 27571882 DOI: 10.1093/Neuonc/Now189  1
2016 Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncology. PMID 27515827 DOI: 10.1093/neuonc/now091  1
2016 Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, et al. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 5: e1145332. PMID 27471611 DOI: 10.1080/2162402X.2016.1145332  1
2016 Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PD-1 blockade enhances the vaccination-induced immune response in glioma. Jci Insight. 1. PMID 27453950 DOI: 10.1172/Jci.Insight.87059  1
2016 Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27298403 DOI: 10.1200/Jco.2016.68.0926  1
2016 Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine. 8: 341ra75. PMID 27252174 DOI: 10.1126/Scitranslmed.Aad9784  1
2016 Laks DR, Crisman TJ, Shih MY, Mottahedeh J, Gao F, Sperry J, Garrett MC, Yong WH, Cloughesy TF, Liau LM, Lai A, Coppola G, Kornblum HI. Large-scale assessment of the gliomasphere model system. Neuro-Oncology. PMID 27116978 DOI: 10.1093/Neuonc/Now045  1
2016 Leu K, Boxerman JL, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB, Ellingson BM. Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. Ajnr. American Journal of Neuroradiology. PMID 27079371 DOI: 10.3174/ajnr.A4759  1
2016 Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, ... ... Cloughesy TF, et al. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 29: 563-73. PMID 27070703 DOI: 10.1016/J.Ccell.2016.03.012  1
2016 Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-Oncology. PMID 27006178 DOI: 10.1093/neuonc/now046  1
2016 Ellingson BM, Nguyen HN, Lai A, Nechifor RE, Zaw O, Pope WB, Yong WH, Nghiemphu PL, Liau LM, Cloughesy TF. Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. Cancer. PMID 26998740 DOI: 10.1002/Cncr.29957  1
2016 Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC, Swanson KR. Reply to comment on: 'Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach'. Physics in Medicine and Biology. 61: 2968-9. PMID 26988701 DOI: 10.1088/0031-9155/61/7/2968  1
2016 Ab KL, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. Journal of Magnetic Resonance Imaging : Jmri. PMID 26971534 DOI: 10.1002/jmri.25227  1
2016 Panosyan EH, Lasky JL, Lin HJ, Lai A, Hai Y, Guo X, Quinn M, Nelson SF, Cloughesy TF, Nghiemphu PL. Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. Journal of Neuro-Oncology. PMID 26922345 DOI: 10.1007/s11060-016-2073-5  1
2016 Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T. Reply to T.J. Kruser et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26884575 DOI: 10.1200/JCO.2015.65.2438  1
2016 Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-Oncology. PMID 26809751 DOI: 10.1093/neuonc/nov300  1
2016 Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26786929 DOI: 10.1200/Jco.2015.63.6563  1
2016 Clark PM, Mai WX, Cloughesy TF, Nathanson DA. Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. Current Neurology and Neuroscience Reports. 16: 17. PMID 26759318 DOI: 10.1007/s11910-015-0613-6  1
2016 Reardon DA, Dietrich J, Kaley T, Gan H, Dunn GP, Cloughesy T, Lim M, Clarke J, Park A, Pan L, Lai DW, Karakunnel J, Robbins P, Narwal R, Venhaus R. Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM) Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A046  1
2016 Reardon DA, Kaley T, Dietrich J, Lim M, Dunn GP, Gan HK, Cloughesy T, Clarke JL, Park A, Macri M, Ryan A, Ricciardi T, Reddy V, Venhaus R. Abstract IA20: Phase II study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naïve patients with recurrent GBM Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Ia20  1
2016 Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WKA, de Groot JF, Fine H, et al. Prioritization schema for immunotherapy clinical trials in glioblastoma Oncoimmunology. DOI: 10.1080/2162402X.2016.1145332  1
2015 Chang W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography : a Journal For Imaging Research. 1: 37-43. PMID 26740971 DOI: 10.18383/j.tom.2015.00115  1
2015 Banerjee P, Leu K, Harris RJ, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB, Bookheimer SY, Ellingson BM. Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. Neuroimage. Clinical. 9: 617-24. PMID 26740915 DOI: 10.1016/j.nicl.2015.10.010  1
2015 Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. PMID 26588662 DOI: 10.1002/cncr.29798  1
2015 Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, Bui Y, Stream A, McBride WH, Liau LM, Nelson SF, Cloughesy TF, Yong WH, Lai A, Tso CL. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Molecular Cancer. 14: 189. PMID 26546412 DOI: 10.1186/S12943-015-0459-1  1
2015 Yong WH, Shabihkhani M, Telesca D, Yang S, Tso JL, Menjivar JC, Wei B, Lucey GM, Mareninov S, Chen Z, Liau LM, Lai A, Nelson SF, Cloughesy TF, Tso CL. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. Plos One. 10: e0141334. PMID 26506620 DOI: 10.1371/Journal.Pone.0141334  1
2015 Huang RY, Rahman R, Ballman KV, Felten S, Anderson K, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26490307 DOI: 10.1158/1078-0432.Ccr-14-3040  1
2015 Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, ... ... Cloughesy TF, et al. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Molecular Cell. PMID 26455392 DOI: 10.1016/J.Molcel.2015.09.002  1
2015 Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology. PMID 26449250 DOI: 10.1093/Neuonc/Nov245  1
2015 Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, ... ... Cloughesy TF, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology. 17: 1188-98. PMID 26250565 DOI: 10.1093/Neuonc/Nov095  1
2015 Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, ... ... Cloughesy TF, et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metabolism. PMID 26190651 DOI: 10.1016/J.Cmet.2015.06.009  1
2015 Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proceedings of the National Academy of Sciences of the United States of America. PMID 26170313 DOI: 10.1073/Pnas.1511759112  1
2015 Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26124478 DOI: 10.1200/JCO.2015.61.5005  1
2015 Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology. PMID 26113557 DOI: 10.1093/Neuonc/Nov106  1
2015 Hathout L, Pope WB, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. Cns Oncology. 4: 247-56. PMID 26095141 DOI: 10.2217/cns.15.16  1
2015 Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-Oncology. PMID 26019185 DOI: 10.1093/neuonc/nov083  1
2015 Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2166-75. PMID 26014298 DOI: 10.1200/JCO.2014.60.3217  1
2015 Hathout L, Ellingson BM, Cloughesy TF, Pope WB. Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. Oncology Reports. 33: 2883-8. PMID 25962999 DOI: 10.3892/or.2015.3926  1
2015 Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology. 17: 1051-63. PMID 25934816 DOI: 10.1093/Neuonc/Nov031  1
2015 Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP, McDonald KL. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro-Oncology. PMID 25910840 DOI: 10.1093/neuonc/nov064  1
2015 Ellingson BM, Lai A, Nguyen HN, Nghiemphu PL, Pope WB, Cloughesy TF. Quantification of nonenhancing tumor burden in gliomas using effective T2 maps derived from dual-echo turbo spin-echo MRI. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25901082 DOI: 10.1158/1078-0432.CCR-14-2862  1
2015 Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nature Reviews. Cancer. 15: 302-10. PMID 25855404 DOI: 10.1038/nrc3918  1
2015 Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM. MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology. 122: 497-505. PMID 25773062 DOI: 10.1007/s11060-015-1755-8  1
2015 Qiao XJ, Ellingson BM, Kim HJ, Wang DJ, Salamon N, Linetsky M, Sepahdari AR, Jiang B, Tian JJ, Esswein SR, Cloughesy TF, Lai A, Nghiemphu L, Pope WB. Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma. Ajnr. American Journal of Neuroradiology. 36: 672-7. PMID 25542879 DOI: 10.3174/ajnr.A4196  1
2015 Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 17: 434-42. PMID 25465392 DOI: 10.1007/S11307-014-0807-3  1
2015 Hathout L, Ellingson BM, Cloughesy T, Pope WB. A novel bicompartmental mathematical model of glioblastoma multiforme. International Journal of Oncology. 46: 825-32. PMID 25384756 DOI: 10.3892/ijo.2014.2741  1
2015 Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, et al. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro-Oncology. 17: 180-8. PMID 25165194 DOI: 10.1093/Neuonc/Nou154  1
2014 Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biology & Medicine. 11: 255-63. PMID 25610711 DOI: 10.7497/j.issn.2095-3941.2014.04.004  1
2014 Leu K, Enzmann DR, Woodworth DC, Harris RJ, Tran AN, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 14: 31. PMID 25608485 DOI: 10.1186/s40644-014-0031-z  1
2014 Baldock AL, Ahn S, Rockne R, Johnston S, Neal M, Corwin D, Clark-Swanson K, Sterin G, Trister AD, Malone H, Ebiana V, Sonabend AM, Mrugala M, Rockhill JK, Silbergeld DL, ... ... Cloughesy T, et al. Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. Plos One. 9: e99057. PMID 25350742 DOI: 10.1371/Journal.Pone.0099057  1
2014 Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-Oncology. 16: vii36-47. PMID 25313237 DOI: 10.1093/neuonc/nou226  1
2014 Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. Neuro-Oncology. 16: vii2-11. PMID 25313235 DOI: 10.1093/neuonc/nou224  1
2014 Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, ... Cloughesy TF, et al. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5808-22. PMID 25224277 DOI: 10.1158/1078-0432.Ccr-14-0234  1
2014 Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, et al. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology. 16: 1541-6. PMID 24997140 DOI: 10.1093/Neuonc/Nou083  1
2014 Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 2049. PMID 24860870 DOI: 10.1056/Nejmc1403303  1
2014 Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 2048-9. PMID 24849088 DOI: 10.1056/NEJMc1403303  1
2014 Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3550-9. PMID 24687922 DOI: 10.1158/1078-0432.Ccr-13-1440  1
2014 Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, ... ... Cloughesy TF, et al. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro-Oncology. 16: 815-22. PMID 24627236 DOI: 10.1093/Neuonc/Nou028  1
2014 Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors. European Journal of Nuclear Medicine and Molecular Imaging. 41: 1199-209. PMID 24604590 DOI: 10.1007/S00259-013-2678-2  1
2014 Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England Journal of Medicine. 370: 709-22. PMID 24552318 DOI: 10.1056/NEJMoa1308345  1
2014 Panosyan EH, Wang Y, Xia P, Lee WN, Pak Y, Laks DR, Lin HJ, Moore TB, Cloughesy TF, Kornblum HI, Lasky JL. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Molecular Cancer Research : McR. 12: 694-702. PMID 24505127 DOI: 10.1158/1541-7786.MCR-13-0576  1
2014 Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 271: 200-10. PMID 24475840 DOI: 10.1148/radiol.13131305  1
2014 Avliyakulov NK, Rajavel KS, Le KM, Guo L, Mirsadraei L, Yong WH, Liau LM, Li S, Lai A, Nghiemphu PL, Cloughesy TF, Linetsky M, Haykinson MJ, Pope WB. C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. Journal of Neuro-Oncology. 117: 53-65. PMID 24473683 DOI: 10.1007/S11060-014-1371-Z  1
2014 Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. 16: 567-78. PMID 24470557 DOI: 10.1093/Neuonc/Not247  1
2014 Shabihkhani M, Lucey GM, Wei B, Mareninov S, Lou JJ, Vinters HV, Singer EJ, Cloughesy TF, Yong WH. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clinical Biochemistry. 47: 258-66. PMID 24424103 DOI: 10.1016/J.Clinbiochem.2014.01.002  1
2014 Zaw TM, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Ellingson BM. Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. Journal of Neuro-Oncology. 116: 601-8. PMID 24395348 DOI: 10.1007/s11060-013-1344-7  1
2014 Woodworth DC, Pope WB, Liau LM, Kim HJ, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. Journal of Neuro-Oncology. 116: 551-8. PMID 24318915 DOI: 10.1007/s11060-013-1320-2  1
2014 Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, ... ... Cloughesy TF, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science (New York, N.Y.). 343: 72-6. PMID 24310612 DOI: 10.1126/Science.1241328  1
2014 Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro-Oncology. 16: 603-9. PMID 24305722 DOI: 10.1093/Neuonc/Not166  1
2014 Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro-Oncology. 16: 414-20. PMID 24305712 DOI: 10.1093/neuonc/not198  1
2014 Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, et al. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro-Oncology. 16: 173-8. PMID 24305708 DOI: 10.1093/Neuonc/Not229  1
2014 Harris RJ, Bookheimer SY, Cloughesy TF, Kim HJ, Pope WB, Lai A, Nghiemphu PL, Liau LM, Ellingson BM. Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. Journal of Neuro-Oncology. 116: 373-9. PMID 24234804 DOI: 10.1007/s11060-013-1304-2  1
2014 Ellingson BM, Sahebjam S, Kim HJ, Pope WB, Harris RJ, Woodworth DC, Lai A, Nghiemphu PL, Mason WP, Cloughesy TF. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. Ajnr. American Journal of Neuroradiology. 35: 673-9. PMID 24136647 DOI: 10.3174/ajnr.A3748  1
2014 Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annual Review of Pathology. 9: 1-25. PMID 23937436 DOI: 10.1146/annurev-pathol-011110-130324  1
2014 White CM, Pope WB, Zaw T, Qiao J, Naeini KM, Lai A, Nghiemphu PL, Wang JJ, Cloughesy TF, Ellingson BM. Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 24: 23-30. PMID 22672084 DOI: 10.1111/j.1552-6569.2012.00703.x  1
2014 Banerjee P, Cloughesy T, Pham J, Cervantes S, Nghiemphu P, Lai A, Wellisch D. Ql-05Self-Reported Cognitive Difficulties And Associated Medical Characteristics In Patients With Adult-Onset Glioma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou269.5  1
2014 Kang J, Selch MT, Kupelian P, Cloughesy T, Lee P. High-Dose Radiation to the Subventricular Zone Does Not Alter the Patterns of Recurrence in GB International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.05.991  1
2014 Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, ... ... Cloughesy TF, et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling Cell Metabolism. DOI: 10.1016/j.cmet.2015.06.009  1
2013 Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. Pet Clinics. 8: 201-17. PMID 27157948 DOI: 10.1016/J.Cpet.2012.09.002  1
2013 Leu K, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Chen W, Liau LM, Ellingson BM. Imaging biomarkers for antiangiogenic therapy in malignant gliomas. Cns Oncology. 2: 33-47. PMID 24570837 DOI: 10.2217/cns.12.29  1
2013 Al-Dabbagh TQ, Alherabi AZ. Multiple myeloma presenting as dysphagia. Saudi Medical Journal. 34: 1304. PMID 24343475  0.01
2013 Aljasser MI, Al-Omair IA. Propylene glycol allergic contact dermatitis. A quick reference guide for propylene glycol-free topical corticosteroids in Saudi Arabia. Saudi Medical Journal. 34: 1302-3. PMID 24343474  0.01
2013 Cheng H, Hong W, Wang X, Hu X. Diffusion tensor imaging findings associated with cognitive performance in hydrocephalus patients. Saudi Medical Journal. 34: 1299-301. PMID 24343473  0.01
2013 Alherabi AZ, Marglani OA, Gazzaz MJ, Abbas MM. Paraspinal tuberculosis mimicking malignancy. Saudi Medical Journal. 34: 1296-8. PMID 24343472  0.01
2013 Celik O, Ipekci T, Kazimoglu H. Idiopathic scrotal calcinosis. Saudi Medical Journal. 34: 1294-5. PMID 24343471  0.01
2013 Al-Ateeq MA, Al-Rusaiess AA, Al-Dughaither AA. Perceptions and effects of antenatal education. Saudi Medical Journal. 34: 1287-93. PMID 24343470  0.01
2013 Ayoub MD, Radi SA, Azab AM, Abulaban AA, Balkhoyor AH, Bedair SW, Aljaouni SK, Kari JA. Quality of life among children with beta-thalassemia major treated in Western Saudi Arabia. Saudi Medical Journal. 34: 1281-6. PMID 24343469  0.01
2013 Isa HM, Mohamed AM. Neonatal hemochromatosis. Case series from Bahrain. Saudi Medical Journal. 34: 1274-80. PMID 24343468  0.01
2013 Zhang M, Sun J. Bone metastasis from ovarian cancer. Clinical analysis of 26 cases. Saudi Medical Journal. 34: 1270-3. PMID 24343467  0.01
2013 Al-Harthi SE, Khan LM, Abed HH, Alkreathy HM, Ali AS. Appraisal of antimicrobial prescribing practices of governmental and non-governmental dentists for hospitals in the western region of Saudi Arabia. Saudi Medical Journal. 34: 1262-9. PMID 24343466  0.01
2013 Al-Katheri AE. Impact of backpack load on ventilatory function among 9-12 year old Saudi girls. Saudi Medical Journal. 34: 1255-61. PMID 24343465  0.01
2013 Al-Shafei AI, El-Gendy OA. Effects of Roselle on arterial pulse pressure and left ventricular hypertrophy in hypertensive patients. Saudi Medical Journal. 34: 1248-54. PMID 24343464  0.01
2013 Nasr AY. Morphological, biochemical, histological, and ultrastructural protective effects of misoprostol on cisplatin induced-hepatotoxicity in adult male rats. Saudi Medical Journal. 34: 1237-47. PMID 24343463  0.01
2013 Chen Y, Yan J, Yuan Z, Yu S, Wang Z, Zheng Q. A meta-analysis of robotic-assisted pancreatectomy versus laparoscopic and open pancreatectomy. Saudi Medical Journal. 34: 1229-36. PMID 24343462  0.01
2013 Pu YW, Gong W, Wu YY, Chen Q, He TF, Xing CG. Proximal gastrectomy versus total gastrectomy for proximal gastric carcinoma. A meta-analysis on postoperative complications, 5-year survival, and recurrence rate. Saudi Medical Journal. 34: 1223-8. PMID 24343461  0.01
2013 Meena S, Singla A, Chowdhury B. Making advanced trauma life support more effective. Saudi Medical Journal. 34: 1121-2. PMID 24343460  0.01
2013 Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, McBride W, Tso CL. Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. Plos One. 8: e80397. PMID 24260384 DOI: 10.1371/Journal.Pone.0080397  1
2013 Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metabolism. 18: 726-39. PMID 24140020 DOI: 10.1016/J.Cmet.2013.09.013  1
2013 Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, ... ... Cloughesy TF, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5722-32. PMID 24030701 DOI: 10.1158/1078-0432.Ccr-13-0527  1
2013 Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, ... ... Cloughesy TF, et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metabolism. 17: 1000-8. PMID 23707073 DOI: 10.1016/J.Cmet.2013.04.013  1
2013 Mareninov S, De Jesus J, Sanchez DE, Kay AB, Wilson RW, Babic I, Chen W, Telesca D, Lou JJ, Mirsadraei L, Gardner TP, Khanlou N, Vinters HV, Shafa BB, Lai A, ... ... Cloughesy TF, et al. Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. Journal of Neuro-Oncology. 113: 365-73. PMID 23640138 DOI: 10.1007/S11060-013-1135-1  1
2013 Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle (Georgetown, Tex.). 12: 1473-4. PMID 23624839 DOI: 10.4161/cc.24747  1
2013 Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Reply to B. Freidlin et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 970-1. PMID 23565532 DOI: 10.1200/JCO.2012.47.4403  1
2013 Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, ... ... Cloughesy TF, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.Cd-12-0502  1
2013 Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloëguen Y, Cloughesy TF. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Current Neurology and Neuroscience Reports. 13: 347. PMID 23529375 DOI: 10.1007/s11910-013-0347-2  1
2013 Lee P, Eppinga W, Lagerwaard F, Cloughesy T, Slotman B, Nghiemphu PL, Wang PC, Kupelian P, Agazaryan N, Demarco J, Selch MT, Steinberg M, Kang JJ. Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis. International Journal of Radiation Oncology, Biology, Physics. 86: 609-15. PMID 23462418 DOI: 10.1016/J.Ijrobp.2013.01.009  1
2013 Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, Chowdhury R, Phillips HS, Nghiemphu PL, Behbahanian Y, Ellingson BM. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro-Oncology. 15: 626-34. PMID 23444259 DOI: 10.1093/neuonc/not008  1
2013 Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 4339-44. PMID 23440206 DOI: 10.1073/Pnas.1217602110  1
2013 Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Sioletic S, Sullivan LM, ... ... Cloughesy T, et al. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathology (Zurich, Switzerland). 23: 565-73. PMID 23438035 DOI: 10.1111/Bpa.12043  1
2013 Neal ML, Trister AD, Ahn S, Baldock A, Bridge CA, Guyman L, Lange J, Sodt R, Cloke T, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Research. 73: 2976-86. PMID 23400596 DOI: 10.1158/0008-5472.Can-12-3588  1
2013 Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 152-7. PMID 23377664 DOI: 10.1097/Cji.0B013E3182811Ae4  1
2013 Neal ML, Trister AD, Cloke T, Sodt R, Ahn S, Baldock AL, Bridge CA, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. Plos One. 8: e51951. PMID 23372647 DOI: 10.1371/Journal.Pone.0051951  1
2013 Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan ?, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, ... ... Cloughesy TC, et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics. 45: 253-61. PMID 23354438 DOI: 10.1038/Ng.2538  1
2013 Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, et al. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Targeted Oncology. 8: 117-25. PMID 23345034 DOI: 10.1007/s11523-013-0254-0  1
2013 Harris RJ, Cloughesy TF, Pope WB, Godinez S, Natsuaki Y, Nghiemphu PL, Meyer H, Paul D, Behbahanian Y, Lai A, Ellingson BM. Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. Journal of Neuro-Oncology. 112: 257-66. PMID 23344788 DOI: 10.1007/s11060-013-1057-y  1
2013 Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, ... ... Cloughesy TF, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology. 15: 370-81. PMID 23328811 DOI: 10.1093/Neuonc/Nos308  1
2013 Albarrak A, Alokaily F. A year of challenges and opportunities. Saudi Medical Journal. 34: 3-5. PMID 23299152  0.01
2013 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro-Oncology. 15: 382-90. PMID 23275575 DOI: 10.1093/neuonc/nos314  1
2013 Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro-Oncology. 15: 4-27. PMID 23136223 DOI: 10.1093/neuonc/nos273  1
2013 Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, Wu KC, Faull KF, Cloughesy T, Liau LM, Lai A. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro-Oncology. 15: 57-68. PMID 23115158 DOI: 10.1093/Neuonc/Nos261  1
2013 Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, Pope WB, Nghiemphu PL, Vinters HV, Liau LM, Mischel PS, Cloughesy TF. Probabilistic radiographic atlas of glioblastoma phenotypes. Ajnr. American Journal of Neuroradiology. 34: 533-40. PMID 22997168 DOI: 10.3174/Ajnr.A3253  1
2013 Yong WH, Shabihkhani M, Su KC, Wei B, Lucey GM, Mareninov S, Kuo-Bonde LE, Pope WB, Cloughesy TF. Brainstem gliomas: Clinicopathologic features and a practical diagnostic approach for pathologists Pathology Case Reviews. 18: 237-242. DOI: 10.1097/Pcr.0B013E3182A9Ac78  1
2013 Acquaye AA, Vera-Bolanos E, Gilbert MR, Armstrong TS, Lin L, Amidei C, Lovely M, Arzbaecher J, Page M, Mogensen K, Lupica K, Maher ME, Won M, Wefel JS, Pugh S, ... ... Cloughesy T, et al. Symptom Management/Quality Of Life Neuro-Oncology. 15. DOI: 10.1093/Neuonc/Not192  1
2013 Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, Groot Jd, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, ... ... Cloughesy T, ... ... Cloughesy T, et al. Neuro/Medical Oncology Neuro-Oncology. 15: 120-120. DOI: 10.1093/Neuonc/Not182  1
2013 Wick W, Cloughesy T, Mason W, Henriksson R, Saran F, Nishikawa R, Hilton M, Garcia J, Pallaud C, Chinot O. Efficacy and biomarker findings from AVaglio, a phase III trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma Journal of the Neurological Sciences. 333. DOI: 10.1016/J.Jns.2013.07.2268  1
2013 Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PET parametric response mapping for clinical monitoring and treatment response evaluation in brain tumors Pet Clinics. 8: 201-217. DOI: 10.1016/j.cpet.2012.09.002  1
2012 Bakhsh ZT, Mansour AY, Mensah EK, Croke KG, Drummond JL, Koerber A. Factors affecting the internal brain drain of Saudi healthcare professionals. Saudi Medical Journal. 33: 1285-9. PMID 23232675  0.01
2012 Tourkmani AM, Al Khashan HI, Albabtain MA, Al Harbi TJ, Al Qahatani HB, Bakhiet AH. Medication adherence among patients in a chronic disease clinic. Saudi Medical Journal. 33: 1278-84. PMID 23232674  0.01
2012 Albarrak AM, Stephens GM, Hewson R, Memish ZA. Recovery from severe novel coronavirus infection. Saudi Medical Journal. 33: 1265-9. PMID 23232672  0.01
2012 Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, ... ... Cloughesy TF, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro-Oncology. 14: 1511-8. PMID 23099651 DOI: 10.1093/Neuonc/Nos264  1
2012 Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro-Oncology. 14: 1465-72. PMID 23090985 DOI: 10.1093/Neuonc/Nos258  1
2012 Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, ... ... Cloughesy T, et al. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. Journal of the National Cancer Institute. 104: 1458-69. PMID 22945948 DOI: 10.1093/Jnci/Djs357  1
2012 Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6032-9. PMID 22923449 DOI: 10.1158/1078-0432.Ccr-12-1841  1
2012 Nghiemphu PL, Lai A, Green RM, Reardon DA, Cloughesy T. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. Journal of Neuro-Oncology. 110: 245-50. PMID 22918789 DOI: 10.1007/s11060-012-0960-y  1
2012 Piccioni D, Lai A, Nghiemphu P, Cloughesy T. Bevacizumab as first-line therapy for glioblastoma. Future Oncology (London, England). 8: 929-38. PMID 22894667 DOI: 10.2217/fon.12.81  1
2012 Nghiemphu PL, Cloughesy T. Glioblastoma therapy in the elderly: one age does not fit all. The Lancet. Oncology. 13: 857-8. PMID 22877850 DOI: 10.1016/S1470-2045(12)70368-6  1
2012 Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro-Oncology. 14: 1079-89. PMID 22711609 DOI: 10.1093/Neuonc/Nos141  1
2012 Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, et al. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-Oncology. 14: 761-7. PMID 22661585 DOI: 10.1093/Neuonc/Nos065  1
2012 Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3258-63. PMID 22649140 DOI: 10.1200/JCO.2011.39.8420  1
2012 Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, ... ... Cloughesy TF, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery. 2: 458-71. PMID 22588883 DOI: 10.1158/2159-8290.Cd-11-0284  1
2012 Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. The Lancet. Oncology. 13: e196-204. PMID 22554547 DOI: 10.1016/S1470-2045(11)70406-5  1
2012 Mong S, Ellingson BM, Nghiemphu PL, Kim HJ, Mirsadraei L, Lai A, Yong W, Zaw TM, Cloughesy TF, Pope WB. Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. Ajnr. American Journal of Neuroradiology. 33: 1763-70. PMID 22538078 DOI: 10.3174/Ajnr.A3053  1
2012 Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, ... ... Cloughesy T, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology. 108: 491-8. PMID 22426926 DOI: 10.1007/s11060-012-0847-y  1
2012 Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69: 1507-18. PMID 22392572 DOI: 10.1007/S00280-012-1854-6  1
2012 Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 393-8. PMID 22323780 DOI: 10.2967/Jnumed.111.095711  1
2012 Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. Ajnr. American Journal of Neuroradiology. 33: 1349-55. PMID 22322613 DOI: 10.3174/Ajnr.A2950  1
2012 Ellingson BM, Zaw T, Cloughesy TF, Naeini KM, Lalezari S, Mong S, Lai A, Nghiemphu PL, Pope WB. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. Journal of Magnetic Resonance Imaging : Jmri. 35: 1472-7. PMID 22281731 DOI: 10.1002/jmri.23600  1
2012 Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalezari S, Wagle N, Naeini KM, Carrillo J, Liau LM, Pope WB. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro-Oncology. 14: 333-43. PMID 22270220 DOI: 10.1093/neuonc/nor220  1
2012 Pope WB, Mirsadraei L, Lai A, Eskin A, Qiao J, Kim HJ, Ellingson B, Nghiemphu PL, Kharbanda S, Soriano RH, Nelson SF, Yong W, Phillips HS, Cloughesy TF. Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. Ajnr. American Journal of Neuroradiology. 33: 1059-64. PMID 22268080 DOI: 10.3174/Ajnr.A2917  1
2012 Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 29-36. PMID 22159180 DOI: 10.2967/Jnumed.111.092387  1
2012 Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology. 38: 271-91. PMID 22098029 DOI: 10.1111/J.1365-2990.2011.01238.X  1
2012 Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, ... ... Cloughesy TF, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Journal of Neuro-Oncology. 107: 197-205. PMID 22015945 DOI: 10.1007/S11060-011-0737-8  1
2012 Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Current Topics in Microbiology and Immunology. 355: 135-69. PMID 22015553 DOI: 10.1007/82_2011_178  1
2012 Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 59: 908-16. PMID 22001163 DOI: 10.1016/j.neuroimage.2011.09.076  1
2012 Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemotherapy and Pharmacology. 69: 281-7. PMID 21984222 DOI: 10.1007/s00280-011-1754-1  1
2012 Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. Journal of Neuro-Oncology. 106: 147-53. PMID 21739168 DOI: 10.1007/S11060-011-0650-1  1
2012 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology. 106: 111-9. PMID 21706273 DOI: 10.1007/s11060-011-0638-x  1
2012 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magnetic Resonance in Medicine. 67: 237-45. PMID 21702063 DOI: 10.1002/mrm.23003  1
2012 Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, DeAngelis LM. Response to C. Massard et al Journal of Clinical Oncology. 30: 563-564. DOI: 10.1200/JCO.2011.40.1513  1
2012 Furuse M, Miyatake S, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Karajannis MA, Fisher MJ, Milla SS, Cohen KJ, Legault G, Wisoff JH, Harter DH, Hartnett E, Merkelson A, ... ... Cloughesy T, ... ... Cloughesy TF, et al. Clin-Ongoing Clinical Trials Neuro-Oncology. 14. DOI: 10.1093/Neuonc/Nos232  1
2012 Park C-, Kim Y-, Kim JW, Kim TM, Choi SH, Kim YJ, Choi BS, Lee S-, Kim C-, Kim IH, Lee DZ, Kheder A, Forbes M, Craven I, Hadjivassiliou M, ... ... Cloughesy TF, ... ... Cloughesy T, et al. Clin-Neuro/Medical Oncology Neuro-Oncology. 14. DOI: 10.1093/Neuonc/Nos229  1
2012 Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Gregory Cairncross J, Urgoiti GBR, Wen PY, Ligon KL, Schiff D, et al. Response to Weltman and Fleury Malheiros, re Lassman et al. Neuro-Oncology. 14: 677-678. DOI: 10.1093/Neuonc/Nos136  1
2012 Kang J, Selch M, Cloughesy T, Kupelian P, Pajonk F, Wang J, Agazaryan N, Lee P. Radiation of Potential Local Cancer Stem Cell Niches Improves Survival of Patients With Glioblastoma Multiforme International Journal of Radiation Oncology*Biology*Physics. 84: S6-S7. DOI: 10.1016/J.Ijrobp.2012.07.023  1
2011 Lai A, Lalezari S, Chou AP, Tran A, Solis OE, Carrillo JA, Chen W, Mischel PS, Green RM, Nghiemphu PL, Liau LM, Wang H, Elashoff RM, Cloughesy TF, Yong WH. Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2003. PMID 28023883 DOI: 10.1200/Jco.2011.29.15_Suppl.2003  1
2011 Wen PY, Puduvalli VK, Kuhn JG, Reid JM, Lamborn K, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Desideri S, et al. Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2032. PMID 28023819 DOI: 10.1200/jco.2011.29.15_suppl.2032  1
2011 De Groot JF, Cloughesy T, Lieberman FS, Chang SM, Omuro AM, Drappatz J, Batchelor T, DeAngelis LM, Gilbert MR, Yung WK, Fisher JD, Ye X, Lamborn K, Chen AP, Grossman SA, et al. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2043. PMID 28023799 DOI: 10.1200/jco.2011.29.15_suppl.2043  1
2011 Chinot OL, Wick W, Saran F, Mason WP, Henriksson R, Nishikawa R, Zeaiter AH, Moore N, Das A, Cloughesy TF. AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS136. PMID 28022889 DOI: 10.1200/jco.2011.29.15_suppl.tps136  1
2011 Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, ... ... Cloughesy TF, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discovery. 1: 524-38. PMID 22145100 DOI: 10.1158/2159-8290.Cd-11-0124  1
2011 Cloughesy T. The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma. Seminars in Oncology. 38: S11-20. PMID 22078643 DOI: 10.1053/j.seminoncol.2011.09.007  1
2011 Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, ... ... Cloughesy TF, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discovery. 1: 442-56. PMID 22059152 DOI: 10.1158/2159-8290.Cd-11-0102  1
2011 Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, ... ... Cloughesy T, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4482-90. PMID 22025148 DOI: 10.1200/Jco.2010.33.8715  1
2011 Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, Wheeler H, Eskin A, Schmid I, Yong WH, Mischel PS, ... Cloughesy TF, et al. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Molecular Cancer Research : McR. 9: 1668-85. PMID 22013079 DOI: 10.1158/1541-7786.Mcr-10-0563  1
2011 Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6553-62. PMID 21868765 DOI: 10.1158/1078-0432.Ccr-10-3290  1
2011 Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 1151-61. PMID 21856685 DOI: 10.1093/Neuonc/Nor079  1
2011 Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-Oncology. 13: 1118-24. PMID 21813511 DOI: 10.1093/Neuonc/Nor110  1
2011 Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, et al. It is time to include patients with brain tumors in phase I trials in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3211-3. PMID 21768451 DOI: 10.1200/Jco.2011.36.6328  1
2011 Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-Oncology. 13: 649-59. PMID 21636710 DOI: 10.1093/Neuonc/Nor040  1
2011 de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4872-81. PMID 21632852 DOI: 10.1158/1078-0432.Ccr-11-0271  1
2011 de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2689-95. PMID 21606416 DOI: 10.1200/Jco.2010.34.1636  1
2011 Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 660-8. PMID 21558074 DOI: 10.1093/Neuonc/Nor024  1
2011 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. High order diffusion tensor imaging in human glioblastoma. Academic Radiology. 18: 947-54. PMID 21536466 DOI: 10.1016/j.acra.2011.02.020  1
2011 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology. 105: 91-101. PMID 21442275 DOI: 10.1007/s11060-011-0567-8  1
2011 Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Advances in Therapy. 28: 334-40. PMID 21432029 DOI: 10.1007/s12325-011-0007-3  1
2011 Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. Ajnr. American Journal of Neuroradiology. 32: 882-9. PMID 21330401 DOI: 10.3174/Ajnr.A2385  1
2011 Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 401-9. PMID 21324937 DOI: 10.1093/neuonc/noq206  1
2011 Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro-Oncology. 13: 353-61. PMID 21310734 DOI: 10.1093/Neuonc/Noq203  1
2011 Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncology. 13: 437-46. PMID 21297127 DOI: 10.1093/neuonc/noq198  1
2011 Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, Huo J, Brown MS, Goldin J, Cloughesy T. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 76: 432-7. PMID 21282590 DOI: 10.1212/WNL.0b013e31820a0a8a  1
2011 Kay AB, Estrada DK, Mareninov S, Silver SS, Magyar CE, Dry SM, Cloughesy TF, Yong WH. Considerations for uniform and accurate biospecimen labelling in a biorepository and research environment. Journal of Clinical Pathology. 64: 634-6. PMID 21217091 DOI: 10.1136/Jcp.2010.080655  1
2011 Cloughesy TF, Mischel PS. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6-11. PMID 21208902 DOI: 10.1158/1078-0432.CCR-09-2268  1
2011 Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, ... ... Cloughesy T, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 142-8. PMID 21135282 DOI: 10.1200/Jco.2010.30.2729  1
2011 Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 143-51. PMID 21084434 DOI: 10.1093/Neuonc/Noq151  1
2011 Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, ... ... Cloughesy TF, et al. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. International Journal of Radiation Oncology, Biology, Physics. 81: 1422-7. PMID 20934264 DOI: 10.1016/J.Ijrobp.2010.07.1997  1
2011 Solis OE, Mehta RI, Lai A, Mehta RI, Farchoukh LO, Green RM, Cheng JC, Natarajan S, Vinters HV, Cloughesy T, Yong WH. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. Journal of Neuro-Oncology. 102: 477-84. PMID 20872044 DOI: 10.1007/S11060-010-0335-1  1
2011 Youssef M, Reinitz F, Cloughesy T, Mischel P, Guo D. Abstract C169: Inhibition of SREBPs by fatostatin reduces glioblastoma cell proliferation and viability. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C169  1
2010 Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmacogenomics and Personalized Medicine. 3: 79-85. PMID 23226044 DOI: 10.2147/Pgpm.S7940  1
2010 Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. The Oncologist. 15: 1329-34. PMID 21147867 DOI: 10.1634/Theoncologist.2010-0105  1
2010 Cloughesy T. FDA accelerated approval benefits glioblastoma. The Lancet. Oncology. 11: 1120. PMID 21126686 DOI: 10.1016/S1470-2045(10)70269-2  1
2010 Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1532-8. PMID 20847166 DOI: 10.2967/Jnumed.110.078592  1
2010 Bindayna K, Khanfar HS, Senok AC, Botta GA. Predominance of CTX-M genotype among extended spectrum beta lactamase isolates in a tertiary hospital in Saudi Arabia. Saudi Medical Journal. 31: 859-63. PMID 20714681  0.01
2010 Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology. 12: 1061-70. PMID 20615922 DOI: 10.1093/Neuonc/Noq072  1
2010 Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, Lazareff JA, Mischel PS, Moore TB, Kornblum HI. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatric Blood & Cancer. 55: 644-51. PMID 20589659 DOI: 10.1002/Pbc.22627  1
2010 Rockne R, Rockhill JK, Mrugala M, Spence AM, Kalet I, Hendrickson K, Lai A, Cloughesy T, Alvord EC, Swanson KR. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Physics in Medicine and Biology. 55: 3271-85. PMID 20484781 DOI: 10.1088/0031-9155/55/12/001  1
2010 Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Oncology. 12: 882-9. PMID 20472883 DOI: 10.1093/neuonc/noq052  1
2010 Al-Omani SF. Evolution and role of the Hospitalist program at Riyadh Military Hospital. Saudi Medical Journal. 31: 483-5. PMID 20464034  0.01
2010 Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 720-7. PMID 20395318 DOI: 10.2967/Jnumed.109.068361  1
2010 Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, ... ... Cloughesy TF, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America. 107: 6459-64. PMID 20308550 DOI: 10.1073/Pnas.0911188107  1
2010 Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1963-72. PMID 20231676 DOI: 10.1200/Jco.2009.26.3541  1
2010 Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology. 12: 95-103. PMID 20150372 DOI: 10.1093/Neuonc/Nop015  1
2010 Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro-Oncology. 12: 87-94. PMID 20150371 DOI: 10.1093/Neuonc/Nop017  1
2010 Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle (Georgetown, Tex.). 9: 211-2. PMID 20023392 DOI: 10.4161/Cc.9.2.10540  1
2010 Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodríguez-Ponce MI, et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. Journal of Neurosurgery. 113: 301-9. PMID 20020841 DOI: 10.3171/2009.11.Jns091052  1
2010 Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. Genomic landscape of meningiomas. Brain Pathology (Zurich, Switzerland). 20: 751-62. PMID 20015288 DOI: 10.1111/J.1750-3639.2009.00356.X  1
2010 Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, ... ... Cloughesy TF, et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics. 42: 77-82. PMID 19946270 DOI: 10.1038/Ng.491  1
2010 Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. Journal of Neuro-Oncology. 96: 359-67. PMID 19655089 DOI: 10.1007/s11060-009-9983-4  1
2010 Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology. 96: 211-7. PMID 19562255 DOI: 10.1007/S11060-009-9948-7  1
2010 Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Reply to W. Wick et al Journal of Clinical Oncology. 28: e190-e192. DOI: 10.1200/Jco.2009.26.9472  1
2009 Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P. Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2062. PMID 27964693 DOI: 10.1200/jco.2009.27.15_suppl.2062  1
2009 Green RM, Cloughesy T, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB. Bevacizumab for recurrent ependymoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2060. PMID 27964675 DOI: 10.1200/jco.2009.27.15_suppl.2060  1
2009 Wefel JS, Cloughesy T, Zazzali J, Yi J, Friedman HS. Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2056. PMID 27964669 DOI: 10.1200/Jco.2009.27.15_Suppl.2056  1
2009 Lai A, Nghiemphu P, Green R, Spier L, Peak S, Phuphanich S, Fehrenbacher L, Kolevska T, Polikoff J, Cloughesy T. Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2000. PMID 27964565 DOI: 10.1200/jco.2009.27.15_suppl.2000  1
2009 Prados M, Gilbert M, Kuhn J, Lamborn K, Cloughesy T, Lieberman F, Puduvalli V, Robins HI, Lassman A, Wen PY. Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2005. PMID 27964562 DOI: 10.1200/jco.2009.27.15_suppl.2005  1
2009 Chang SM, Kuhn J, Lamborn K, Cloughesy T, Robins I, Lieberman F, Yung A, Dancey J, Prados M, Wen P. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2004. PMID 27964561 DOI: 10.1200/jco.2009.27.15_suppl.2004  1
2009 Wen PY, Cloughesy T, Kuhn J, Lamborn K, Abrey LE, Lieberman F, Robins HI, Wright J, Prados MD, Gilbert M. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2006. PMID 27964559 DOI: 10.1200/jco.2009.27.15_suppl.2006  1
2009 Kuhn JG, Gilbert M, Wen P, Cloughesy T, Cooper J, Puduvalli V, DeAngelis L, Lieberman F, Lamborn K, Prados M. Interaction between sorafenib and erlotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2500. PMID 27961962 DOI: 10.1200/jco.2009.27.15_suppl.2500  1
2009 Tran A, Escovedo C, Migdall-Wilson J, Chou AP, Chen W, Cloughesy T, Nelson S, Lai A. In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays. Frontiers in Neuroscience. 3: 57. PMID 20582289 DOI: 10.3389/Neuro.15.005.2009  0.4
2009 Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, ... ... Cloughesy TF, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science Signaling. 2: ra82. PMID 20009104 DOI: 10.1126/Scisignal.2000446  1
2009 Wang CH, Rockhill JK, Mrugala M, Peacock DL, Lai A, Jusenius K, Wardlaw JM, Cloughesy T, Spence AM, Rockne R, Alvord EC, Swanson KR. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Research. 69: 9133-40. PMID 19934335 DOI: 10.1158/0008-5472.CAN-08-3863  1
2009 Green RM, Cloughesy TF, Stupp R, DeAngelis LM, Woyshner EA, Ney DE, Lassman AB. Bevacizumab for recurrent ependymoma. Neurology. 73: 1677-80. PMID 19917990 DOI: 10.1212/WNL.0b013e3181c1df34  1
2009 Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4733-40. PMID 19720927 DOI: 10.1200/Jco.2008.19.8721  1
2009 Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... Cloughesy TF, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.Can-09-0347  1
2009 Al-Mendalawi MD, Telatar B, Kartal LT. The effect of maternal anemia on anthropometric measurements of newborns. Saudi Medical Journal. 30: 1110-1; author reply. PMID 19668902  0.01
2009 Pellicano R, Fagoonee S. Uninvestigated dyspepsia and its related factors in an Iranian community. Saudi Medical Journal. 30: 1109; author reply 1. PMID 19668901  0.01
2009 Alavian SM, Tabatabaei SV, Ayyub M. Outcome of combination antiviral therapy in hepatitis C virus infected patients with sickle cell disease. Saudi Medical Journal. 30: 1107-8; author reply. PMID 19668900  0.01
2009 Al-Mendalawi MD. Anemic crisis due to Mycoplasma pneumoniae complication in sickle cell patients. Saudi Medical Journal. 30: 1105. PMID 19668899  0.01
2009 Deris ZZ, Hasan H, Sulaiman SA, Wahab MS, Naing NN, Othman NH. Preference of treatment facilities among Malaysian Hajj pilgrims for acute respiratory symptoms. Saudi Medical Journal. 30: 1103-4. PMID 19668898  0.01
2009 Abdul-Wahab A, Janahi IA, Abdel-Rahman MO. Sweat chloride concentration in cystic fibrosis patients with cystic fibrosis trans-membrane conductance regulator I1234V mutation. Saudi Medical Journal. 30: 1101-2. PMID 19668897  0.01
2009 Ozkan S, Gemicioglu B, Durna Z, Demir T. Turkish version of the functional performance inventory used on patients with chronic obstructive pulmonary disease. Saudi Medical Journal. 30: 1098-100. PMID 19668896  0.01
2009 Younes NA, Al-Ardah MI, Daradkeh SS. Rupture of spleen post colonoscopy. Saudi Medical Journal. 30: 1095-7. PMID 19668895  0.01
2009 Al-Sherbeeni NM. Salmonella species group B causing endocarditis of the prosthetic mitral valve. Saudi Medical Journal. 30: 1091-4. PMID 19668894  0.01
2009 Nasser T, Qari F. Pheochromocytoma, papillary thyroid carcinoma. Saudi Medical Journal. 30: 1087-90. PMID 19668893  0.01
2009 Malki KH, Al-Habib SF, Hagr AA, Farahat MM. Acoustic analysis of normal Saudi adult voices. Saudi Medical Journal. 30: 1081-6. PMID 19668892  0.01
2009 Arikan I, Metintas S, Kalyoncu C, Colak O, Arikan U. Evaluation of metabolic syndrome prevalence in semi-rural areas of Central Anatolia, Turkey. Saudi Medical Journal. 30: 1073-80. PMID 19668891  0.01
2009 Alhomoud IA, Bohlega SA, Alkawi MZ, Alsemari AM, Omer SM, Alsenani FM. Primary Sjogren's syndrome with central nervous system involvement. Saudi Medical Journal. 30: 1067-72. PMID 19668890  0.01
2009 Sigari N, Mohammadi S. Anthracosis and anthracofibrosis. Saudi Medical Journal. 30: 1063-6. PMID 19668889  0.01
2009 El-Habbash MM, Alwindi AA. Male breast cancer in Tripoli, Libya. Saudi Medical Journal. 30: 1060-2. PMID 19668888  0.01
2009 Al-Saran KA, Elsayed SA, Molhem AJ, AlDrees AS, AlZara HM. Nutritional assessment of patients in a large Saudi dialysis center. Saudi Medical Journal. 30: 1054-9. PMID 19668887  0.01
2009 Liu G, Huang Y, Lu XW, Lu M, Huang XT, Li WM, Jiang ME. Optimization of the model of abdominal aortic aneurysm by co-incubation of calcium chloride and collagenase in rats. Saudi Medical Journal. 30: 1049-53. PMID 19668886  0.01
2009 Mahafzah AM, Daradkeh SS. Profile and predictors of bile infection in patients undergoing laparoscopic cholecystectomy. Saudi Medical Journal. 30: 1044-8. PMID 19668885  0.01
2009 Hadidy AM, Samara OA, Takrouri HS, Al-Ryalat NT, Al-Smady MM, Ryalat ST, Abu-Khalaf MM. Uncommon incidental pseudoaneurysm. Diagnostic and management challenges. Saudi Medical Journal. 30: 1037-43. PMID 19668884  0.01
2009 Moradan S, Ghorbani R. Dexamethasone in unexplained infertility. Saudi Medical Journal. 30: 1034-6. PMID 19668883  0.01
2009 Sayyah-Melli M, Tehrani-Gadim S, Dastranj-Tabrizi A, Gatrehsamani F, Morteza G, Ouladesahebmadarek E, Farzadi L, Kazemi-Shishvan M. Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes. Saudi Medical Journal. 30: 1024-33. PMID 19668882  0.01
2009 Asghar AH, Faidah HS. Frequency and antimicrobial susceptibility of gram-negative bacteria isolated from 2 hospitals in Makkah, Saudi Arabia. Saudi Medical Journal. 30: 1017-23. PMID 19668881  0.01
2009 Song W, Yuan M, Zhao S. Variation of M3 muscarinic receptor expression in different prostate tissues and its significance. Saudi Medical Journal. 30: 1010-6. PMID 19668880  0.01
2009 Tang L, Sun H, Zhang L, Deng JC, Guo H, Zhang L, Liu Q. Effects of the augmenter of liver regeneration on the biological behavior of hepatocellular carcinoma. Saudi Medical Journal. 30: 1001-9. PMID 19668879  0.01
2009 Dalcik C, Yildirim GK, Dalcik H. The effects of ethanol on insulin-like growth factor-I immunoreactive neurons in the central nervous system. Saudi Medical Journal. 30: 995-1000. PMID 19668878  0.01
2009 Brindley PG, Arabi YM. An introduction to medical simulation. Saudi Medical Journal. 30: 991-4. PMID 19668877  0.01
2009 Iwanami A, Cloughesy TF, Mischel PS. Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes & Development. 23: 1699-704. PMID 19651981 DOI: 10.1101/gad.1832909  1
2009 Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proceedings of the National Academy of Sciences of the United States of America. 106: 12932-7. PMID 19625624 DOI: 10.1073/Pnas.0906606106  1
2009 Al-Deeb SM. Farewell from the Editor-In-Chief. After 18 enjoyable years. Saudi Medical Journal. 30: 869-71. PMID 19617997  0.01
2009 McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 16: 44-54. PMID 19573811 DOI: 10.1016/J.Ccr.2009.05.009  1
2009 Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 252: 182-9. PMID 19561256 DOI: 10.1148/Radiol.2521081534  1
2009 Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 500-12. PMID 19560740 DOI: 10.1016/J.Nurt.2009.04.008  1
2009 Al-Mendalawi MD. Leishmaniasis resembling hematological malignancies. The concern of differential diagnosis. Saudi Medical Journal. 30: 857; author reply 85. PMID 19526178  0.01
2009 Vatansever SH, Inan SV, Giray GS, Sayhan S, Ozbilgin KM, Sanci M. The distribution of apoptosis and related proteins in ovarian endometriosis. Saudi Medical Journal. 30: 855-6. PMID 19526177  0.01
2009 Battah AH, Al-Farras MI, Abdallat IM, Hadidi MS. Trends of carbon monoxide fatalities in Jordan. Saudi Medical Journal. 30: 853-4. PMID 19526176  0.01
2009 Saquib S, Mathew M, Jain R. Torsion of a non-gravid uterus with leiomyoma mimicking broad ligament leiomyoma. Saudi Medical Journal. 30: 851-2. PMID 19526175  0.01
2009 Almasswary AA. Very late stent thrombosis in a bare-metal stent, 9 years after implantation. Saudi Medical Journal. 30: 847-50. PMID 19526174  0.01
2009 Alotaibi HM. An unusual association of recurrent pyogenic granuloma on nevus flammeus in a patient with Von Recklinghausen's disease. Saudi Medical Journal. 30: 844-6. PMID 19526173  0.01
2009 El-Essawy MT. Extraskeletal Ewing's sarcoma. Saudi Medical Journal. 30: 840-3. PMID 19526172  0.01
2009 Kosaryan M, Vahidshahi K, Siami R, Nazari M, Karami H, Ehteshami S. Knowledge, attitude, and practice of reproductive behavior in Iranian minor thalassemia couples. Saudi Medical Journal. 30: 835-9. PMID 19526171  0.01
2009 Al-Quaiz AJ, Raheel HM. Correlates of sexual violence among adolescent females in Riyadh, Saudi Arabia. Saudi Medical Journal. 30: 829-34. PMID 19526170  0.01
2009 Saleh HK. Pattern of congenital heart disease in Southern Yemeni children referred for echocardiography. Saudi Medical Journal. 30: 824-8. PMID 19526169  0.01
2009 Omran MT, Khakpour S, Oliaie F. Left ventricular function before and after kidney transplantation. Saudi Medical Journal. 30: 821-3. PMID 19526168  0.01
2009 Tacoy GA, Yazici GE, Kocaman SA, Ozdemir MH. Thrombolysis in myocardial infarction frame count in coronary arteries without visible atherosclerosis in coronary angiography of patients with stable coronary artery disease. Saudi Medical Journal. 30: 817-20. PMID 19526167  0.01
2009 Abdollahi SF, Bahlouli A, Mostafa PG, Rasooli S, Morteza G. Comparison of laparoscopy-assisted hysterectomies with conventional hysterectomies. Saudi Medical Journal. 30: 813-6. PMID 19526166  0.01
2009 Al-Omran AS, Sadat-Ali M. Arthroscopic joint lavage in osteoarthritis of the knee. Is it effective? Saudi Medical Journal. 30: 809-12. PMID 19526165  0.01
2009 Memon JI, Rehmani RS, Ahmed MU, Elgendy AM, Nizami IY. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. Saudi Medical Journal. 30: 803-8. PMID 19526164  0.01
2009 Hanif G, Ali SI, Shahid A, Rehman F, Mirza U. Role of biopsy in pediatric lymphadenopathy. Saudi Medical Journal. 30: 798-802. PMID 19526163  0.01
2009 Khadadah ME, Muqim AT, Al-Mutairi AD, Nahar IK, Sharma PN, Behbehani NH, El-Maradni NM. Closed percutaneous pleural biopsy. A lost art in the new era. Saudi Medical Journal. 30: 793-7. PMID 19526162  0.01
2009 Al B, Yildirim C, Zengin S, Cavdar M, Togun I. The effect of chronic carbon-monoxide exposure on the peak expiratory flow values of grill-kebab chefs. Saudi Medical Journal. 30: 788-92. PMID 19526161  0.01
2009 Hudaoglu OG, Uçar SK, Atlihan F, Dizdarer C, Büyükgebiz A. The effects of topical iodine containing antiseptics on thyroidal status of preterm versus term babies. Saudi Medical Journal. 30: 783-7. PMID 19526160  0.01
2009 Unal Y, Ozsoylar O, Arslan M, Sarigüney D, Akçabay M. Comparison of the efficacy of propofol and metoclopramide in preventing postoperative nausea and vomiting after middle ear surgery. Saudi Medical Journal. 30: 778-82. PMID 19526159  0.01
2009 Gökçe BM, Karabiyik L, Karadenizli Y. Hypotensive anesthesia with esmolol. Assessment of hemodynamics, consumption of anesthetic drugs, and recovery. Saudi Medical Journal. 30: 771-7. PMID 19526158  0.01
2009 Shackebaei D, Kayhani B, Godini A, Pourshanazari A, Reshadat S. The effect of repeated diazepam administration on myocardial function in the ischemia-reperfused isolated rat heart. Saudi Medical Journal. 30: 755-9. PMID 19526155  0.01
2009 Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106  1
2009 Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. Journal of Neuro-Oncology. 94: 1-19. PMID 19468690 DOI: 10.1007/s11060-009-9919-z  1
2009 Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells (Dayton, Ohio). 27: 980-7. PMID 19353526 DOI: 10.1002/Stem.15  1
2009 Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 72: 1217-22. PMID 19349600 DOI: 10.1212/01.Wnl.0000345668.03039.90  1
2009 Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. 11: 853-60. PMID 19293394 DOI: 10.1215/15228517-2009-010  1
2009 Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. Journal of Neuro-Oncology. 91: 183-9. PMID 18850068 DOI: 10.1007/s11060-008-9705-3  1
2009 Remington M, Chtchetinin J, Ancheta K, Nghiemphu PL, Cloughesy T, Lai A. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro-Oncology. 11: 22-32. PMID 18812520 DOI: 10.1215/15228517-2008-080  1
2009 Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of Neuro-Oncology. 91: 175-82. PMID 18797818 DOI: 10.1007/s11060-008-9693-3  1
2009 Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. European Journal of Radiology. 71: 242-8. PMID 18511228 DOI: 10.1016/J.Ejrad.2008.04.018  1
2009 Wen PY, Omuro AM, Batchelor TT, Lai A, Mellinghoff IK, Nghiemphu L, Norden A, Gendreau SB, Laird AD, Nguyen L, Cloughesy T. Abstract B265: A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B265  1
2008 Taira RK, Taira R, Bui A, Bui AA, Hsu W, Bashyam V, Dube S, Watt E, Andrada L, El-Saden S, Cloughesy T, Kangarloo H. A tool for improving the longitudinal imaging characterization for neuro-oncology cases. Amia ... Annual Symposium Proceedings / Amia Symposium. Amia Symposium. 712-6. PMID 18999139  1
2008 Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5610-7. PMID 18981465 DOI: 10.1200/JCO.2008.16.7510  1
2008 Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. Bmc Medical Genomics. 1: 52. PMID 18940004 DOI: 10.1186/1755-8794-1-52  1
2008 Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 249: 268-77. PMID 18796682 DOI: 10.1148/radiol.2491072000  1
2008 Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. The New England Journal of Medicine. 359: 539-41. PMID 18669440 DOI: 10.1056/NEJMc0804818  1
2008 Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro-Oncology. 10: 631-42. PMID 18559968 DOI: 10.1215/15228517-2008-021  1
2008 Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro-Oncology. 10: 355-60. PMID 18436627 DOI: 10.1215/15228517-2008-009  1
2008 Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB. Time course of imaging changes of GBM during extended bevacizumab treatment. Journal of Neuro-Oncology. 88: 339-47. PMID 18389177 DOI: 10.1007/s11060-008-9573-x  1
2008 Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 10: 162-70. PMID 18356283 DOI: 10.1215/15228517-2007-062  1
2008 Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. International Journal of Radiation Oncology, Biology, Physics. 71: 1372-80. PMID 18355978 DOI: 10.1016/J.Ijrobp.2007.11.068  1
2008 Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, ... ... Cloughesy TF, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 488-93. PMID 18223223 DOI: 10.1158/1078-0432.Ccr-07-1966  1
2008 Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. Plos Medicine. 5: e8. PMID 18215105 DOI: 10.1371/Journal.Pmed.0050008  1
2008 Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, ... ... Cloughesy TF, et al. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. Journal of Neuroscience Research. 86: 48-60. PMID 17722061 DOI: 10.1002/Jnr.21471  1
2008 Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemotherapy and Pharmacology. 61: 1059-67. PMID 17694310 DOI: 10.1007/s00280-007-0556-y  1
2008 Dube S, Corso JJ, Yuille A, Cloughesy TF, El-Saden S, Sinha U. Hierarchical segmentation of malignant Gliomas via integrated contextual filter response Progress in Biomedical Optics and Imaging - Proceedings of Spie. 6914. DOI: 10.1117/12.770769  1
2008 Donnan GA, Adams R, Bacellar A, Baron JC, Bath P, Benavente O, Bladin C, Bornstein N, Brainin M, Chambers B, Chen C, Csiba L, Culebras A, Davalos A, Davis S, ... ... Cloughesy T, et al. Editorial International Journal of Stroke. 3: 1-2. DOI: 10.1111/j.1747-4949.2008.00166.x  1
2007 Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7401-6. PMID 18094423 DOI: 10.1158/1078-0432.CCR-07-0781  1
2007 Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, ... ... Cloughesy TF, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America. 104: 20007-12. PMID 18077431 DOI: 10.1073/Pnas.0710052104  1
2007 Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, et al. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7133-8. PMID 18056194 DOI: 10.1158/1078-0432.Ccr-07-0874  1
2007 Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4714-21. PMID 17947718 DOI: 10.1200/Jco.2006.10.5825  1
2007 Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18F-FDOPA kinetics in brain tumors. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1651-61. PMID 17873130 DOI: 10.2967/Jnumed.106.039321  1
2007 Camaggi V, Piscaglia F, Bolondi L. Recent advances in the imaging of hepatocellular carcinoma. From ultrasound to positron emission tomography scan. Saudi Medical Journal. 28: 1007-14. PMID 17603700  0.01
2007 Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2592-8. PMID 17473188 DOI: 10.1158/1078-0432.CCR-06-2772  1
2007 Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. 18F-fluorothymidine kinetics of malignant brain tumors. European Journal of Nuclear Medicine and Molecular Imaging. 34: 1003-11. PMID 17295039 DOI: 10.1007/s00259-006-0354-5  1
2007 Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, ... ... Cloughesy TF, et al. High-throughput oncogene mutation profiling in human cancer. Nature Genetics. 39: 347-51. PMID 17293865 DOI: 10.1038/Ng1975  1
2007 Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 378-81. PMID 17255257 DOI: 10.1158/1078-0432.CCR-06-1992  1
2007 Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Journal of Neuro-Oncology. 81: 271-7. PMID 17031561 DOI: 10.1007/S11060-006-9225-Y  1
2007 Dube S, Corso JJ, Cloughesy TF, El-Saden S, Yuille AL, Sinha U. Automated MR image processing and analysis of malignant brain tumors: Enabling technology for data mining Aip Conference Proceedings. 953: 64-84. DOI: 10.1063/1.2817354  1
2006 Dube S, El-Saden S, Cloughesy TF, Sinha U. Content based image retrieval for MR image studies of brain tumors. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 1: 3337-40. PMID 17946561 DOI: 10.1109/IEMBS.2006.260262  1
2006 Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, ... ... Cloughesy T, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos Medicine. 3: e485. PMID 17177598 DOI: 10.1371/Journal.Pmed.0030485  1
2006 Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, Lee Y, Scheck AC, Liau LM, Wu H, Geschwind DH, ... ... Cloughesy TF, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proceedings of the National Academy of Sciences of the United States of America. 103: 17402-7. PMID 17090670 DOI: 10.1073/pnas.0608396103  1
2006 Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. Primary glioblastomas express mesenchymal stem-like properties. Molecular Cancer Research : McR. 4: 607-19. PMID 16966431 DOI: 10.1158/1541-7786.MCR-06-0005  1
2006 Fedorowicz Z, Lawrence DJ, Gutierrez P. A Cochrane Systematic Review finds no significant difference in outcome or risk of postoperative complications between day care and in-patient cataract surgery. Saudi Medical Journal. 27: 1296-301. PMID 16951761  0.01
2006 Mischel PS, Cloughesy T. Using molecular information to guide brain tumor therapy. Nature Clinical Practice. Neurology. 2: 232-3. PMID 16932555 DOI: 10.1038/ncpneuro0145  1
2006 Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4899-907. PMID 16914578 DOI: 10.1158/1078-0432.Ccr-06-0773  1
2006 Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Research. 66: 7864-9. PMID 16912159 DOI: 10.1158/0008-5472.Can-04-4392  1
2006 Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3651-6. PMID 16877733 DOI: 10.1200/Jco.2006.06.2323  1
2006 Bicer U, Kurtas O, Ercin C, Gundogmus UN, Colak B, Paksoy N. Pain-driven suicide due to pleural plaques associated with asbestos exposure. Saudi Medical Journal. 27: 894-6. PMID 16758060  0.01
2006 Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 47: 904-11. PMID 16741298  1
2006 Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 66: 1258-60. PMID 16636248 DOI: 10.1212/01.Wnl.0000250628.10420.D8  1
2006 Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncology. 8: 189-93. PMID 16533878 DOI: 10.1215/15228517-2005-010  1
2006 Salih MA, Zahraa JN, Al-Jarallah AA, Alorainy IA, Hassan HH. Stroke from systemic vascular disorders in Saudi children. The devastating role of hypernatremic dehydration. Saudi Medical Journal. 27: S97-102. PMID 16532137  0.01
2006 Salih MA, Abdel-Gader AG, Al-Jarallah AA, Kentab AY, Al-Nasser MN. Outcome of stroke in Saudi children. Saudi Medical Journal. 27: S91-6. PMID 16532136  0.01
2006 Salih MA, Abdel-Gader AG, Zahraa JN, Al-Rayess MM, Alorainy IA, Hassan HH, Ruitenbeek W, Zeviani M. Stroke due to mitochondrial disorders in Saudi children. Saudi Medical Journal. 27: S81-90. PMID 16532135  0.01
2006 Salih MA, Murshid WR, Al-Salman MM, Abdel-Gader AG, Al-Jarallah AA, Alorainy IA, Hassan HH, Kentab AY, Van Maldergem L, Othman SA, El-Desouki MI, Elgamal EA. Moyamoya syndrome as a risk factor for stroke in Saudi children. Novel and usual associations. Saudi Medical Journal. 27: S69-80. PMID 16532134  0.01
2006 Salih MA, Al-Jarallah AS, Abdel-Gader AG, Al-Jarallah AA, Al-Saadi MM, Kentab AY, Alorainy IA, Hassan HH. Cardiac diseases as a risk factor for stroke in Saudi children. Saudi Medical Journal. 27: S61-8. PMID 16532133  0.01
2006 Salih MA, Murshid WR, Zahraa JN, Abdel-Gader AG, Al-Jarallah AA, Kentab AY, Alorainy IA, Hassan HH, Tjan GT. Congenital and genetic cerebrovascular anomalies as risk factors for stroke in Saudi children. Saudi Medical Journal. 27: S53-60. PMID 16532132  0.01
2006 Salih MA, Abdel-Gader AG, Al-Jarallah AA, Kentab AY, Gadelrab MO, Alorainy IA, Hassan HH, Zahraa JN. Infectious and inflammatory disorders of the circulatory system as risk factors for stroke in Saudi children. Saudi Medical Journal. 27: S41-52. PMID 16532131  0.01
2006 Salih MA, Abdel-Gader AG. Diagnostic approach and management strategy of childhood stroke. Saudi Medical Journal. 27: S4-11. PMID 16532130  0.01
2006 Salih MA, Abdel-Gader AG, Al-Jarallah AA, Kentab AY, Alorainy IA, Hassan HH, Al-Nasser MN. Perinatal stroke in Saudi children. Clinical features and risk factors. Saudi Medical Journal. 27: S35-40. PMID 16532129  0.01
2006 Salih MA, Abdel-Gader AG, Al-Jarallah AA, Kentab AY, Alorainy IA, Hassan HH, Bahakim HM, Kurbaan KM, Zahraa JN, Murshid WR, El-Hazmi MA, Khoja WA. Hematologic risk factors for stroke in Saudi children. Saudi Medical Journal. 27: S21-34. PMID 16532128  0.01
2006 Salih MA, Abdel-Gader AG, Al-Jarallah AA, Kentab AY, Alorainy IA, Hassan HH, Bahakim HM, Kurbaan KM, Zahraa JN, Al-Nasser MN, Nasir AA, Khoja WA, Kabiraj MM. Stroke in Saudi children. Epidemiology, clinical features and risk factors. Saudi Medical Journal. 27: S12-20. PMID 16532126  0.01
2006 Salih MA, Abdel-Gader AG, Al-Jarallah AA. Study project on stroke in Saudi children. Conclusions, recommendations and acknowledgements. Saudi Medical Journal. 27: S108-10. PMID 16532125  0.01
2006 Salih MA, Al-Jarallah AA, Al-Salman MM, Alorainy IA, Hassan HH. Stroke from cervicocephalic arterial dissection in Saudi children. Saudi Medical Journal. 27: S103-7. PMID 16532124  0.01
2006 Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Research. 66: 159-67. PMID 16397228 DOI: 10.1158/0008-5472.CAN-05-0077  1
2006 Pope WB, Cloughesy T. Reply from the authors [2] Neurology. 67: 2089. DOI: 10.1212/01.wnl.0000250628.10420.d8  1
2005 Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. Ajnr. American Journal of Neuroradiology. 26: 2466-74. PMID 16286386  1
2005 Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, ... ... Cloughesy TF, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England Journal of Medicine. 353: 2012-24. PMID 16282176 DOI: 10.1056/Nejmoa051918  1
2005 Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6647-56. PMID 16170172 DOI: 10.1200/Jco.2005.10.068  1
2005 Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5515-25. PMID 16061868 DOI: 10.1158/1078-0432.CCR-05-0464  1
2005 Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. 23: 357-61. PMID 16012795 DOI: 10.1007/S10637-005-1444-0  1
2005 Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 945-52. PMID 15937304  1
2005 Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. The Journal of Biological Chemistry. 280: 26953-64. PMID 15908427 DOI: 10.1074/jbc.M502614200  1
2005 Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Research. Molecular Brain Research. 136: 99-103. PMID 15893592 DOI: 10.1016/j.molbrainres.2005.01.017  1
2005 Al-Waili NS, Butler G, Abdullah M, Qazi SA. Hyperbaric medicine for necrotizing fasciitis. Saudi Medical Journal. 26: 163-4; author reply . PMID 15756386  0.01
2005 Arya SC, Agarwal N, Agarwal S. Nosocomial urinary tract infection. Saudi Medical Journal. 26: 162. PMID 15756385  0.01
2005 Hutchinson TP. Critical reading and critique of medical articles. Saudi Medical Journal. 26: 160-1. PMID 15756384  0.01
2005 Manzar S. Health insurance. A need of time. Saudi Medical Journal. 26: 158-9. PMID 15756383  0.01
2005 Saricaoglu F, Basgul E, Erden A, Aypar U. Hypovolemic cardiac arrest after dental extraction. An unexpected high-flow maxillar arteriovenous malformation. Saudi Medical Journal. 26: 157-8. PMID 15756382  0.01
2005 Ustun S, Aksoy U, Ersoz G, Yazar S, Kilic E. Anti-Toxoplasma gondii antibodies in patients infected with hepatitis B virus. Saudi Medical Journal. 26: 155-7. PMID 15756381  0.01
2004 Yung A, Vredenburgh J, Cloughesy T, Klencke BJ, Mischel PS, Bigner DD, Aldape K, Vanderburg S, Prados M. Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1555. PMID 28015448 DOI: 10.1200/Jco.2004.22.14_Suppl.1555  1
2004 Prados M, Yung W, Wen P, Junck L, Fink K, Cloughesy T, Robins I, Chang S, Kuhn J. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1504. PMID 28015386 DOI: 10.1200/jco.2004.22.14_suppl.1504  1
2004 Raizer JJ, Abrey LE, Wen P, Cloughesy T, Robins IA, Fine HA, Lieberman F, Puduvalli VK, Fink KL, Prados M. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1502. PMID 28015384 DOI: 10.1200/jco.2004.22.14_suppl.1502  1
2004 Lieberman FS, Cloughesy T, Fine H, Kuhn J, Lamborn K, Malkin M, Robbins HI, Yung WA, Wen P, Prados M. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1510. PMID 28015363 DOI: 10.1200/jco.2004.22.14_suppl.1510  1
Show low-probability matches.